01—Abstract
Summary
Summary of the 10-K filed February 20, 2015. Cited figures are marked; the original filing is the authoritative source.
AbbVie Inc. reported strong financial performance for the fiscal year ended December 31, 2014.
The company experienced a 6% increase in worldwide net sales, reaching $20.0 billiona, primarily driven by the robust performance of HUMIRA and double-digit growth in other key products. Despite facing the loss of exclusivity for its lipid franchise, AbbVie successfully navigated this challenge through strategic product launches and pipeline advancements. The company's focus on research and development continues, with significant investment in areas like immunology, virology/liver disease, and oncology, aiming to address complex and serious diseases.
AbbVie is strategically positioned for future growth, with a pipeline of over 30 compounds in Phase 2 or Phase 3 development. The company also announced an increase in its quarterly cash dividend and a new $5.0 billionb stock repurchase program, signaling confidence in its financial health and commitment to shareholder returns.
Key near-term drivers include the launch of its interferon-free HCV treatment, VIEKIRA PAK, and expanding indications for HUMIRA. The company remains focused on operational efficiency and strategic collaborations to enhance its product portfolio and drive long-term value.
02—Key points
Key Highlights
- AbbVie's worldwide net sales grew 6% to $20.0 billion in 2014, driven by HUMIRA and other key products.
- HUMIRA continues to be a significant growth driver, with global sales increasing 19% on a constant currency basis in 2014.
- The company launched VIEKIRA PAK, an all-oral, short-course, interferon-free therapy for Hepatitis C, in the U.S. in December 2014.
- AbbVie invested $3.3 billion in research and development in 2014, highlighting a commitment to pipeline expansion and innovation.
- The company announced a new $5.0 billion stock repurchase program and increased its quarterly cash dividend, demonstrating a focus on returning capital to shareholders.
- Despite generic competition impacting its lipid franchise, AbbVie demonstrated resilience through strategic growth initiatives.
- AbbVie has a strong pipeline with over 30 compounds or indications in Phase 2 or Phase 3 development, targeting key therapeutic areas.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2014, AbbVie Inc. kept $0.09.
- Revenue$19.96B100.0%
- Cost of revenue−$4.43B22.2%
- Gross profit$15.53B77.8%
- Operating costs−$12.12B60.7%
- Operating income$3.41B17.1%
- Interest, other & tax−$1.65B8.2%
- Net income$1.76B8.8%
Where FY2014 revenue went
$19.96B- SG&A: $7.72B, 39% of revenue
- Cost of revenue: $4.43B, 22% of revenue
- Other operating costs: $4.40B, 22% of revenue
- Net income: $1.76B, 8.8% of revenue
- Interest, other & tax: $1.65B, 8.2% of revenue
Kept 8.8% as net incomeNet income $1.76B · 8.8%
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2014filed February 20, 2015Financial Statements
FY2014 against FY2013
| Line item | FY2014FY2013 | Change |
|---|---|---|
| Revenue | $19.96B$18.79B | +6.2% |
| Cost of Revenue | $4.43B$4.58B | −3.4% |
| Gross Profit | $15.53B$14.21B | +9.3% |
| SG&A Expenses | $7.72B$5.35B | +44.3% |
| Operating Expenses | $16.55B$13.13B | +26.1% |
| Operating Income | $3.41B$5.66B | −39.8% |
| Interest Expense | $429.00M$299.00M | +43.5% |
| Net Income | $1.76B$4.13B | −57.2% |
| EPS (Basic) | $1.11$2.58 | −57.0% |
| EPS (Diluted) | $1.10$2.56 | −57.0% |
| Shares Outstanding (Basic) | 1.59B1.59B | +0.4% |
| Shares Outstanding (Diluted) | 1.61B1.60B | +0.4% |
05—Questions
Frequently Asked Questions
What were AbbVie's main sources of revenue in 2014?
AbbVie's primary source of revenue in 2014 was HUMIRA, which accounted for approximately 63% of total net sales, generating $12.5 billion. Other significant product sales included Synthroid, Creon, and Lupron.
What is the outlook for HUMIRA's patent protection?
AbbVie's principal composition of matter patent for HUMIRA in the United States is expected to expire in December 2016, with the equivalent European Union patent expected to expire in April 2018 for the majority of EU countries. The company is actively pursuing additional indications for HUMIRA to extend its lifecycle and market presence.
How did AbbVie's R&D spending contribute to its business in 2014?
AbbVie invested $3.3 billion in research and development in 2014, supporting its pipeline of over 30 compounds in Phase 2 or Phase 3 development. This investment is crucial for developing new therapies for complex diseases and expanding indications for existing products like HUMIRA.
What are the key risks facing AbbVie, as outlined in the filing?
Key risks include the expiration or loss of patent protection for major products like HUMIRA, increased competition from biosimilars, the potential failure of R&D efforts to yield commercially successful products, and regulatory and pricing pressures in the pharmaceutical industry. The significant reliance on HUMIRA revenues also presents a concentration risk.
06—Continue